ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-2.74 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $41.90M |
| Float | $35.00M |
| % Insiders | 6.33% |
| % Institutions | 69.03% |
Volatility is currently expanding
Nyobolt's Battery Technology Enables Digit 5 to Work More Than 20 Hours in a 24-hour Day SALEM, Ore. and CAMBRIDGE, United Kingdom, Oct. 15, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and physical AI company, today announced that Nyobolt, a pioneer of high-power, ultra-fast charging solutions, is the technology provider to Agility.
Three stocks are seeing unusual options volume this morning , as traders react to a flurry of company-specific headlines.
Built on Over 65,000 Hours of Operation and Commercial Deployments, the Next-Generation Upgrades Let a Single Robot Take On Full Facility Workflows at Scale and Work in Close Proximity to People SALEM, Ore., Sept. 15, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and physical AI company, today unveiled Digit® 5, the next generation of its general-purpose humanoid robot.
Experienced public company finance executive joins Agility as company expands commercial momentum and prepares to become the first publicly listed U.S. pure-play humanoid robotics company. SALEM, Ore.
Bay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments. FREMONT, Calif.
SALEM, Ore. & NEW YORK--(BUSINESS WIRE)--Agility Robotics, Inc. (“Agility” or the “Company”) creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ: CCXI) (“CCXI” or “Churchill XI”), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an importan.
SALEM, Ore. & NEW YORK--(BUSINESS WIRE)--Agility Robotics, Inc. (“Agility” or the “Company”), a leading humanoid robotics and physical AI company, and Churchill Capital Corp XI (NASDAQ: CCXI) (“Churchill”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement (the “Transaction”). Upon closing of the Transaction, the combined company is expected to operate as Agility and be listed on a major North American excha.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CCXI and any ticker you trade — then tracks every position and per-strategy win rate.
